ESC 2024: Insights into RNA as therapeutic target and tool
On the last day of the European Society of Cardiology (ESC) 2024 Congress (2 September), a panel discussed the therapeutic…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy
The results of two subanalyses of the PACMAN-AMI trial were presented on the final day (2 September) of the European…
-
Acepodia collaborates with Pfizer to advance antibody-cell conjugation therapies
Taipei-based biotech Acepodia announced yesterday (3 September) that it has agreed to a collaboration with Pfizer Ignite, a subsidiary of…
-
Are PBMs to blame for high drug prices in the US?
For several decades, a heated debate on the continually rising price of medicines in the US has centred on pharmacy…
-
Arcus Biosciences obtains loan facility with Hercules Capital worth $250m
Arcus Biosciences has announced a loan from financer Hercules Capital valued at as much as $250m, contingent on the advancement…
-
EC upgrades approval for J&J’s Rybrevant/chemotherapy combination in NSCLC
The European Commission (EC) has approved a Type II extension for Johnson and Johnson (J&J)’s immunotherapy Rybrevant (amivantamab), which was…
-
Emergent BioSolutions finalises manufacturing site sale to Bora Pharmaceuticals
Emergent BioSolutions announced that it has finalised the sale of its Baltimore-Camden manufacturing site to the Taiwanese firm Bora Pharmaceuticals.…
-
ReAlta secures FDA orphan drug and fast track designations for GvHD therapy
The US Food and Drug Administration (FDA) has granted an orphan drug designation and fast track designation to ReAlta Life…
-
Sound Pharmaceuticals plans to stick with WuXi amid BIOSECURE Act rumblings
Sound Pharmaceuticals wishes to maintain its relationship with WuXi AppTec for manufacturing its lead Meniere’s disease drug SPI-1005, amidst increasing…
-
Gilead’s PBC therapy Livdelzi bags accelerated approval
Gilead Sciences’ Livdelzi (seladelpar) has received an accelerated approval from the US Food and Drug Administration (FDA) to treat primary…